“A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.”, Front Immunol, vol. 8, p. 149, 2017.
, “Cryopreservation-related loss of antigen-specific IFNγ producing CD4 T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.”, Vaccine, vol. 35, no. 15, pp. 1898-1906, 2017.
, , “Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.”, Mol Ther Methods Clin Dev, vol. 3, p. 16061, 2016.
, ,
“Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.”, PLoS One, vol. 9, no. 10, p. e110228, 2014.
, “A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”, PLoS One, vol. 7, no. 8, p. e41936, 2012.
, “In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”, PLoS One, vol. 6, no. 5, p. e19252, 2011.
, “Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8816, 2010.
, “Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8617, 2010.
, “A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.”, AIDS Res Hum Retroviruses, vol. 26, no. 8, pp. 933-42, 2010.
, “Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”, PLoS One, vol. 5, no. 9, p. e12873, 2010.
, “Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.”, J Infect Dis, vol. 201, no. 5, pp. 720-9, 2010.
, “CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.”, PLoS One, vol. 4, no. 2, p. e4401, 2009.
, “Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.”, PLoS One, vol. 3, no. 4, p. e2043, 2008.
, “A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.”, AIDS Res Hum Retroviruses, vol. 24, no. 6, pp. 873-80, 2008.
, “Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.”, Vaccine, vol. 26, no. 22, pp. 2788-95, 2008.
, ,
“Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled”, J Virol, vol. 80, no. 10, pp. 4717-28, 2006.
,